FDA advisers back gene therapy for rare form of blindness

Heidi Ledford

Nature, 2017, vol. 550, issue 7676, 314-314

Abstract: Therapy that targets disease-causing mutations could become the first of its kind approved for use in the United States.

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature.2017.22819 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:550:y:2017:i:7676:d:10.1038_nature.2017.22819

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature.2017.22819

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().